Combination weekly Taxotere™ with Iressa™ /placebo in metastatic breast cancer

Study identifier:1839IL/0128

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A randomised phase II study: Treatment with daily p.o. Iressa™ (ZD1839) or placebo in combination with weekly IV infusion of docetaxel in patients with metastatic breast cancer

Medical condition

Metastatic Breast Cancer

Phase

Phase 2

Healthy volunteers

Study drug

Gefitinib, Docetaxel

Sex

Female

Actual Enrollment

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Jun 2003

Primary Completion Date: -

Study Completion Date: 01 Jun 2006

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Oslo, Norway

Arms	Assigned Interventions

"There is no result for the study"

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1525&filename=CSR-1839IL-0128.pdf
Download
CSR-1839IL-0128.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca, Norway

+47-21006400

Investigators

Principal Investigator

AstraZeneca Norway Medical Director

AstraZeneca